secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0000950170-25-014543
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics appoints Bryant D. Lim as permanent CFO; base salary $483K
-------------------------------------------------------------------------------

- Bryant D. Lim, previously interim CFO, appointed permanent CFO effective Feb 3, 2025; retains roles of Chief Legal Officer and Corporate Secretary.
- Amended employment agreement provides base salary of $483,000, discretionary bonus up to 40% of base, and option for 200,000 shares vesting over 4 years.
- Severance: nine months of base salary for termination without cause (non-change-of-control); twelve months for termination without cause or good reason related to change of control.
- Option grant vests 25% on first anniversary and 1/48 monthly thereafter, subject to continued service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017025014543/0000950170-25-014543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017025014543/prld-20250203.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-014543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer